Use of Pre-Submission Pathways for Device Approvals

Published on 21/12/2025

Leveraging FDA Pre-Submission Pathways for Medical Device Approvals

Table of Contents

What Is the Pre-Submission (Q-Sub) Program?

The FDA’s Pre-Submission program, often referred to as the Q-Submission or “Q-Sub” process, is a formal pathway that allows medical device sponsors to request feedback from the Center for Devices and Radiological Health (CDRH) or Center for Biologics Evaluation and Research (CBER) before submitting regulatory applications such as:

510(k) Premarket Notification
Investigational Device Exemption (IDE)
PMA (Premarket Approval)
De Novo classification requests
CLIA Waiver by Application

Unlike standard Type A/B/C drug meetings, the Q-Sub process is specific to medical devices and includes a wide range of submission types. Pre-Submissions are voluntary, but highly encouraged—especially for first-time filers or novel technologies.

Types of Interactions Under the Q-Submission Program

The Q-Submission framework supports several communication formats:

Pre-Submissions (Pre-Subs): Detailed FDA feedback on specific regulatory questions prior to filing
Informational Meetings: For introducing a new technology or clinical approach
Study Risk Determinations: Determines whether a clinical study is significant or

non-significant risk (SR/NSR)

Submission Issue Meetings: For resolving questions raised during active review of a submission

Site Determinations: To determine whether a facility qualifies as a manufacturer under FDA definitions

These mechanisms help ensure alignment with regulatory expectations early, reducing downstream delays and deficiencies.

Continue with Structure, Timelines, Case Studies, and Strategic Considerations

Q-Submissions: Key Steps and Timelines

The process for initiating a Pre-Submission is straightforward but requires disciplined planning:

Request Submission: Sponsor submits a Q-Sub request with a cover letter and briefing package via the CDRH portal or ESG (Electronic Submissions Gateway)
Acknowledgement: FDA acknowledges receipt within 15 calendar days
Scheduling: FDA targets a meeting within 60–75 days post-receipt
Meeting: Teleconference or in-person session to discuss questions
Meeting Minutes: FDA provides formal written feedback, usually within 30 days

Feedback provided during a Pre-Sub meeting is non-binding but generally respected in future submissions if the development plan remains unchanged.

Case Study: Pre-Sub for a Novel Diagnostic Device

A sponsor developing an AI-enabled blood test used the Pre-Sub pathway before filing a De Novo request. The sponsor sought feedback on:

Proposed clinical validation endpoints
Software validation and cybersecurity strategy
Human factors usability testing design

The FDA recommended including additional patient population data and modifying the risk analysis. The sponsor updated their design, submitted a robust De Novo application, and received approval within the first review cycle.

How to Draft an Effective Pre-Sub Briefing Document

Cover Letter: Identify type of Q-Sub, device name, and intended use
Device Description: Include diagrams, mechanisms of action, and photos
Regulatory History: Prior communications or submissions
Questions for FDA: Direct and specific, grouped by functional area (e.g., CMC, clinical)
Supporting Data: Clinical summaries, bench testing results, labeling mock-ups

Use structured formats aligned with FDA’s guidance document on “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program.”

Strategic Considerations: When and Why to Use the Q-Sub

Sponsors should strongly consider the Pre-Sub process when:

There is uncertainty about regulatory classification (510(k) vs De Novo vs PMA)
The clinical study involves novel endpoints or populations
Software, cybersecurity, or interoperability are critical features
There is no clear predicate device

The Pre-Sub pathway not only clarifies expectations—it builds goodwill and opens lines of communication with reviewers early in development.

Global Insights: EU and Canadian Equivalents

While the Q-Sub process is U.S.-specific, other jurisdictions have similar mechanisms:

EU MDR: Allows for Scientific Advice through notified bodies
Health Canada: Offers pre-submission meetings for Class III/IV devices

For Canadian device strategies and regulatory timelines, refer to the Health Canada Clinical Trials Database for regulatory pathway references.

Conclusion: Maximize Success Through Early Engagement

The FDA Pre-Submission (Q-Sub) pathway is an underutilized yet powerful tool for device sponsors. By initiating strategic dialogue early, sponsors can de-risk their submissions, fine-tune data generation plans, and prevent avoidable rejections or deficiencies.

Whether filing a 510(k), IDE, or De Novo application, early engagement via the Pre-Sub process can lead to faster approvals, better compliance, and stronger device launch trajectories.